Skip to main content

Table 3 Patient characteristics in the group older than 80 years

From: Early initiation of tolvaptan is associated with early discharge in patients with heart failure regardless of age

  Early use of TLV Delayed use of TLV P value
(n = 40) (n = 61)
Body mass index (kg/m2) 19.4 ± 2.9 19.7 ± 4.2 0.603
NYHA class (II/III/IV) 0/55/6 1/33/6 0.705
CS class (I/II/III) 19/38/4 6/28/6 0.026
Systolic BP (mm Hg) on admission 130.8 ± 22.7 121.5 ± 19.9 0.037
Diastolic BP (mm Hg) on admission 70.3 ± 13.8 64.1 ± 11.5 0.020
Heart rate (bpm) 82.5 ± 20.5 85.5 ± 23.7 0.506
AST (IU/L) 34.0 ± 22.8 40.9 ± 47.0 0.329
ALT (IU/L) 24.1 ± 18.2 31.5 ± 53.4 0.323
eGFR (ml/min/1.73 m2) 43.8 ± 19.4 40.5 ± 22.8 0.431
Hemoglobin (g/dL) 11.4 ± 1.9 11.0 ± 2.1 0.326
Brain natriuretic peptide (pg/mL) 1502.2 ± 211.9 850.2 ± 96.8 0.019
Ejection fraction (%) 51.0 ± 18.1 55.1 ± 18.5 0.268
HFpEF (n, %) 30, 49.2 23, 57.5 0.418
Length of hospital stay 21.3 ± 12.5 32.9 ± 17.9  < 0.001
Time until commencement of TLV from hospitalization 3.0 ± 1.3 13.6 ± 11.6  < 0.001
Length of hospital stay after initiation of TLV 18.3 ± 12.4 19.3 ± 12.7 0.699
  1. NYHA: New York Heart Association, CS: clinical scenario, BP: blood pressure, AST: aspartate aminotransferase, ALT: alanine aminotransferase, eGFR: estimated glomerular filtration rate, HFpEF: heart failure preserved ejection fraction, TLV: tolvaptan. Continuous data are expressed as the mean ± standard deviation or error. P-values were determined using the unpaired t-test